Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €5.61 EUR
Change Today +0.03 / 0.54%
Volume 122.7K
TNG On Other Exchanges
EN Paris
As of 12:35 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

transgene sa (TNG) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/4/14 - €12.95
52 Week Low
03/26/15 - €5.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TRANSGENE SA (TNG)

Related News

No related news articles were found.

transgene sa (TNG) Related Businessweek News

No Related Businessweek News Found

transgene sa (TNG) Details

Transgene S.A., a biopharmaceutical company, engages in the research, design, development, and manufacture of therapeutic vaccines and immunotherapeutic products to treat cancers and chronic infectious diseases. Its principal products under Phase II clinical trials include TG4010 for the treatment of metastatic non-small cell lung cancer in combination with chemotherapy; Pexa-Vec primarily for the treatment for liver cancer; TG4001, a therapeutic vaccine for oropharyngeal cancer caused by an infection by the human papilloma virus (HPV); and TG4040 for the treatment of chronic hepatitis C. The company has agreements with Novartis for the development of TG4010 to treat various cancers; Jennerex Biotherapeutics, Inc. for the development and marketing of Pexa-Vec, an oncolytic product; and European Organization for Research and Treatment of Cancer for the development of TG4001 to treat HPV induced head and neck cancers. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene S.A. is a subsidiary of TSGH SAS.

266 Employees
Last Reported Date: 03/24/15
Founded in 1979

transgene sa (TNG) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: €72.2K
Compensation as of Fiscal Year 2013.

transgene sa (TNG) Key Developments

Transgene SA, 2014 Earnings Call, Mar 25, 2015

Transgene SA, 2014 Earnings Call, Mar 25, 2015

Transgene SA Announces Consolidated Financial Results for the Fiscal Year Ended December 31, 2014

Transgene SA announced consolidated financial results for the fiscal year ended December 31, 2014. Revenue was €11,752,000 compared to €15,735,000 a year ago. Operating loss was €46,932,000 compared to €41,198,000 a year ago. Loss before tax was €47,733,000 compared to €41,928,000 a year ago. Net loss was €48,556,000 compared to €42,858,000 a year ago. Diluted loss per share was €1.26 compared to €1.34 a year ago. Net cash generated used in operating activities was €54,236,000 compared to €50,185,000 a year ago. Acquisition of property, plant and equipment was €2,463,000 compared to €1,962,000 a year ago. Acquisition of intangible assets was €139,000 compared to €222,000 a year ago.

Transgene SA to Report Fiscal Year 2014 Results on Mar 24, 2015

Transgene SA announced that they will report fiscal year 2014 results on Mar 24, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNG:FP €5.61 EUR +0.03

TNG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNG.
View Industry Companies

Industry Analysis


Industry Average

Valuation TNG Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRANSGENE SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at